Ultrasound Molecular Imaging of VEGFR-2 in Clear-Cell Renal Cell Carcinoma Tracks Disease Response to Antiangiogenic and Notch-Inhibition Therapy,Theranostics

当前位置： X-MOL 学术 › Theranostics › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Ultrasound Molecular Imaging of VEGFR-2 in Clear-Cell Renal Cell Carcinoma Tracks Disease Response to Antiangiogenic and Notch-Inhibition Therapy
Theranostics ( IF 12.4 ) Pub Date : 2018-01-01 , DOI: 10.7150/thno.19658
Juan D Rojas ₁ , Fanglue Lin ₁ , Yun-Chen Chiang ₂ , Anna Chytil ₃ , Diana C Chong ₄ , Victoria L Bautch _{2,

4,

5} , W Kimryn Rathmell ₃ , Paul A Dayton _{1,

2}

Affiliation

Metastatic clear-cell renal cell carcinoma (ccRCC) affects thousands of patients worldwide each year. Antiangiogenic therapy has been shown to have beneficial effects initially, but resistance is eventually developed. Therefore, it is important to accurately track the response of cancer to different therapeutics in order to appropriately adjust the therapy to maximize efficacy. Change in tumor volume is the current gold standard for determining efficacy of treatment. However, functional variations can occur much earlier than measurable volume changes. Contrast-enhanced ultrasound (CEUS) is an important tool for assessing tumor progression and response to therapy, since it can monitor functional changes in the physiology. In this study, we demonstrate how ultrasound molecular imaging (USMI) can accurately track the evolution of the disease and molecular response to treatment.

中文翻译：

透明细胞肾细胞癌中 VEGFR-2 的超声分子成像追踪疾病对抗血管生成和 Notch 抑制治疗的反应

转移性透明细胞肾细胞癌 (ccRCC) 每年影响全球数千名患者。抗血管生成治疗最初已被证明具有有益效果，但最终会产生耐药性。因此，准确跟踪癌症对不同治疗方法的反应以适当调整治疗方案以最大限度地提高疗效非常重要。肿瘤体积的变化是目前确定治疗效果的金标准。然而，功能变化可能比可测量的体积变化更早发生。超声造影（CEUS）是评估肿瘤进展和治疗反应的重要工具，因为它可以监测生理功能变化。在这项研究中，我们展示了超声分子成像 (USMI) 如何准确跟踪疾病的演变和对治疗的分子反应。

更新日期：2018-01-01

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11